The information within this site is intended for Northern Ireland healthcare professionals to provide balanced, scientific, and evidence based answers to unsolicited medical questions.

Search Medical Information

By searching, I confirm my query is unsolicited. Please note that, depending on your search, some materials provided on this website may describe the use of Pfizer medicines outside the terms of their licence.

Quick Finder

Convenient links to frequently asked questions.

Didn’t find what you were looking for? 

Contact us

Medical Inquiry

Submit your medical enquiry on a Pfizer medicine

Call 01304 616161*

*Speak live with a Pfizer Medical Information professional regarding your medical enquiry from Monday to Thursday between 09:00 AM and 17:00 PM and Friday between 09:00 AM and 16:00 PM (excluding holidays).

Report Adverse Event

Drug Safety Unit 

In the event of a suspected adverse event or side effect with no associated medical information enquiry, please report via www.pfizersafetyreporting.com
If you have a medical information enquiry including those with associated adverse events, contact Medical Information.

MHRA

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Reporting an adverse event for the Covid-19 mRNA vaccines

Reporting an adverse event for the Covid-19 mRNA vaccines 

If you are concerned about an adverse event it should be reported on a Yellow Card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. When reporting please include the vaccine brand and batch/Lot number if available.

Alternatively, adverse events of concern in association with the COVID-19 mRNA vaccines can be reported to Pfizer Medical Information on 01304 616161 or via www.pfizersafetyreporting.com
 
Please do not report the same adverse event(s) to both systems as all reports will be shared between Pfizer and MHRA (in an anonymized form) and dual reporting will create unnecessary duplicates.